Cargando…
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
Despite emerging targeted and immunotherapy treatments, no monoclonal antibodies or antibody-drug conjugates (ADCs) directly targeting tumor cells are currently approved for melanoma therapy. The tumor-associated antigen chondroitin sulphate proteoglycan 4 (CSPG4), a neural crest glycoprotein over-e...
Autores principales: | Hoffmann, Ricarda M., Crescioli, Silvia, Mele, Silvia, Sachouli, Eirini, Cheung, Anthony, Chui, Connie K., Andriollo, Paolo, Jackson, Paul J. M., Lacy, Katie E., Spicer, James F., Thurston, David E., Karagiannis, Sophia N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226475/ https://www.ncbi.nlm.nih.gov/pubmed/32331483 http://dx.doi.org/10.3390/cancers12041029 |
Ejemplares similares
-
The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
por: Schiffer, Davide, et al.
Publicado: (2018) -
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
por: Ilieva, Kristina M., et al.
Publicado: (2018) -
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020) -
Chondroitin Sulfate Proteoglycan CSPG4 as a Novel Hypoxia-Sensitive Marker in Pancreatic Tumors
por: Keleg, Shereen, et al.
Publicado: (2014) -
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)